Associations between the cytotoxic T lymphocyte antigen 4 polymorphisms and risk of bone sarcomas

作者：Fan, Changchun; Zhao, Xuechun; Xu, Zhixing^*

来源：Tumor Biology, 2015, 36(1): 227-231.

DOI：10.1007/s13277-014-2621-6

• CTLA-4
• Bone sarcomas
• Polymorphism
• Meta-analysis

Cytotoxic T lymphocyte antigen 4 (CTLA-4) genetic polymorphisms are implicated to be associated with susceptibility to bone sarcomas, but published studies have reported inconclusive results. The objective of our study was to conduct a meta-analysis investigating the associations between CTLA-4 gene polymorphisms and risk of bone sarcomas. PubMed and Embase databases were searched for all articles published up to June 2, 2013. Odds ratio (OR) with a 95 % confidence interval (95 % CI) was used to assess the association. Finally, 11 individual studies with a total of 2,951 cases with bone sarcomas and 3,396 controls were included in the meta-analysis. There were four studies on the CTLA-4 49G/A polymorphism, three studies on CTLA-4 318C/T polymorphism, two studies on CTLA-4 1661A/G polymorphism, and two studies on CTLA-4 60A/G polymorphism. Overall, CTLA-4 49G/A polymorphism was obviously associated with risk of bone sarcomas (A vs. G: OR=1.36, 95 % CI=1.20-1.54; AA vs. GG: OR=2.24, 95 % CI=1.67-2.99; AA vs. AG/GG: OR=2.00, 95 % CI=1.53-2.62; AA/GA vs. GG: OR=1.35, 95 % CI=1.14-1.61). However, CTLA-4 318C/T, 1661A/G, and 60A/G polymorphisms were not associated with risk of bone sarcomas. The current meta-analysis suggests that CTLA-4 49G/A polymorphism is obviously associated with risk of bone sarcomas. More studies are needed to further evaluate the associations between CTLA-4 polymorphisms and risk of bone sarcomas.

• 出版日期2015-1
• 单位上海交通大学